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Research
Polychlorinated biphenyls (PCBs) are syn-
thetic chemicals that were produced commer-
cially in the United States from 1929 to 1977
and used widely in the electrical industry
because of their high stability, dielectric prop-
erties, and resistance to oxidation (U.S. EPA
and Environment Canada 2004). They were
also used in plasticizers, adhesives, and
hydraulic ﬂuids (Silberhorn et al. 1990; Smith
and Brown 1987). PCBs have long half-lives,
correlated with the degree of chlorination, and
persist in humans and in the environment
(Brown and Lawton 2001; Hansen 1998).
Increasing concern in the 1970s about poten-
tial health and environmental risks led to a
1977 ban on PCB production and distribution
in the United States.
The International Agency for Research on
Cancer (IARC) classified PCBs as probable
human carcinogens (2A) with sufficient evi-
dence of carcinogenicity in animals but limited
evidence from human studies (IARC 1987).
The U.S. Environmental Protection Agency
(EPA) also classiﬁed PCBs as probable human
carcinogens [Integrated Risk Information
System (IRIS) 1996]. The National Toxicology
Program (NTP) has classiﬁed several PCB mix-
tures as “reasonably anticipated to be human
carcinogens” since 1981 (NTP 2005).
The human carcinogenicity of PCBs
remains an important issue. Almost 30 years
after production was banned, PCBs are still a
potential occupational exposure. According to
the U.S. EPA and Environment Canada
(2004), at least 44% (87,000) of PCB trans-
formers and 10% (143,000) of PCB capaci-
tors were disposed of between 1994 and 2000.
However, as many as 113,000 PCB trans-
formers and 1.33 million PCB capacitors may
still be in use. Those who repair and maintain
capacitors and transformers containing PCBs
and those in the reclamation industry respon-
sible for disassembly of PCB-containing
capacitors and transformers have the highest
potential for exposure.
This update of a cohort mortality study
among workers exposed to PCBs in an elec-
trical capacitor manufacturing plant in
Indiana was undertaken because the carcino-
genicity of PCBs in humans is unresolved,
and because on initial follow-up, both poten-
tial latency and statistical power were limited.
The primary purpose was to investigate fur-
ther the increased risks for brain cancer and
malignant melanoma originally observed in
the cohort followed through 1984 (Sinks et al.
1992). Other a priori hypotheses were that
PCB exposure would affect all-cause mor-
tality, all cancer mortality, and, specifically,
rectal, liver, biliary tract, and gallbladder
cancer and non-Hodgkin lymphoma, for
which other studies indicated increased risks
(Brown 1987; Brown and Jones 1981;
Rothman et al. 1997). We updated mortality
through 1998, adding 14 years of follow-up.
Materials and Methods
Capacitors were manufactured at an Indiana
facility, using PCBs as a dielectric ﬂuid from
fall 1957 until spring 1977, when PCBs were
replaced with isopropyl biphenyl (Jones
1977). Two dielectric ﬂuid formulations were
used, Aroclor 1242 through 1971 and Aroclor
1016 from 1971 to 1977 (Jones 1977). In
both formulations, dichlorobiphenyls to
tetrachlorobiphenyls predominated, but
Aroclor 1242 contained 5.5% pentachlori-
nated and hexachlorinated biphenyls versus
0.4% pentachlorinated biphenyls for Aroclor
1016 (Albro and Parker 1979; Hutzinger
et al. 1985). Aroclor composition could vary
from batch to batch (de Voogt and Brinkman
1989; Kimbrough 1995).
Capacitor production began by winding
foil and ﬁlm into bales in a dust-free room with
minimal exposure to PCBs, placing bales in
metal capacitor boxes, and welding boxes shut.
Capacitors were impregnated with dielectric
fluid in a heated vacuum chamber. Large
capacitors requiring gallons of dielectric ﬂuid
were ﬁlled manually through ports on the top
(reportedly resulting in spillage and extensive
dermal contact with dielectric ﬂuid). The ports
of the filled, warm, wet capacitors were sol-
dered shut, dielectric ﬂuid was washed off the
outside, and capacitors were sent to quality
control for testing. No regular industrial
hygiene monitoring was done at the facility. All
operations were under one roof with partitions
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An Indiana capacitor-manufacturing cohort (n = 3,569) was exposed to polychlorinated biphenyls
(PCBs) from 1957 to 1977. The original study of mortality through 1984 found excess melanoma
and brain cancer; other studies of PCB-exposed individuals have found excess non-Hodgkin lym-
phoma and rectal, liver, biliary tract, and gallbladder cancer. Mortality was updated through 1998.
Analyses have included standardized mortality ratios (SMRs) and 95% conﬁdence intervals (CIs)
using rates for Indiana and the United States, standardized rate ratios (SRRs), and Poisson regression
rate ratios (RRs). Estimated cumulative exposure calculations used a new job–exposure matrix.
Mortality overall was reduced (547 deaths; SMR, 0.81; 95% CI, 0.7–0.9). Non-Hodgkin lymphoma
mortality was elevated (9 deaths; SMR, 1.23; 95% CI, 0.6–2.3). Melanoma remained in excess
(9 deaths; SMR, 2.43; 95% CI, 1.1–4.6), especially in the lowest tertile of estimated cumulative
exposure (5 deaths; SMR, 3.72; 95% CI, 1.2–8.7). Seven of the 12 brain cancer deaths (SMR, 1.91;
95% CI, 1.0–3.3) occurred after the original study. Brain cancer mortality increased with exposure
(in the highest tertile, 5 deaths; SMR, 2.71; 95% CI, 0.9–6.3); the SRR dose–response trend was
signiﬁcant (p = 0.016). Among those working ≥ 90 days, both melanoma (8 deaths; SMR, 2.66;
95% CI, 1.1–5.2) and brain cancer (11 deaths; SMR, 2.12; 95% CI, 1.1–3.8) were elevated, espe-
cially for women: melanoma, 3 deaths (SMR, 5.99; 95% CI, 1.2–17.5); brain cancer, 3 deaths
(SMR, 2.87; 95% CI, 0.6–8.4). These ﬁndings of excess melanoma and brain cancer mortality con-
ﬁrm results of the original study. Melanoma mortality was not associated with estimated cumulative
exposure. Brain cancer mortality did not demonstrate a clear dose–response relationship with esti-
mated cumulative exposure. Key words: cancer, cohort study, exposure assessment, occupational
exposure, polychlorinated biphenyls. Environ Health Perspect 114:18–23 (2006).
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and a few specific processes were isolated by
walls (Jones 1977).
In spring 1977, the National Institute for
Occupational Safety and Health (NIOSH)
collected 9 skin smear samples, 16 area sam-
ples, and 40 personal air samples to evaluate
exposures to PCBs and other chemicals. Low
levels of xylene (mean, 1.8 ppm) and toluene
(mean, 2.7 ppm) were found for painters, and
appreciable levels of 1,1,1-trichloroethane
(7–339 ppm) were found in the degreaser area
and trichloroethylene (62–290 ppm) in the
plating and welding areas (Jones 1977).
Exposure assessment for the original mor-
tality study (Sinks et al. 1992) was based on
duration of employment in jobs judged to have
high direct PCB exposure (impregnating, seal-
ing, and testing capacitors), based on personal
and area air sampling. About 10% of the work
force was estimated to have had such exposure
(Sinks et al. 1992).
Exposure assessment for this update was
based on a newly created semiquantitative job–
exposure matrix (JEM) (Nilsen et al. 2004). All
unique jobs (n = 884) were categorized based
on PCB exposure intensity and frequency,
qualitatively ranked for both inhalation and
dermal exposure. For inhalation exposure
intensity, air concentration data permitted
assignment of exposure units (parts per mil-
lion), but for dermal exposure intensity, the
lack of historical dermal exposure measure-
ments resulted in a unitless measure of expo-
sure. For each job category, the product of
intensity and frequency (fraction of day
exposed) was calculated. The inhalation and
dermal JEMs were modiﬁed for an earlier and
a later era (the former with estimated 20%
higher exposure). Because dermal exposures
account for a significant proportion of total
PCB exposure (Fischbein et al. 1982), a com-
bination JEM averaging inhalation and dermal
(1:1) scores was used to estimate cumulative
PCB exposure. Cumulative exposure was
expressed in unit-days of exposure (but the
“unit” was not deﬁned).
The cohort includes 3,569 of the 3,643
workers ever employed at the facility (74 were
ineligible). For the original study (Sinks et al.
1992), vital status was ascertained through
1984. For the update, we submitted names of
cohort members to the National Death Index
(NDI 2005) for determination of vital status
through 31 December 1998, and obtained
death certiﬁcates or NDI-Plus causes of death
(CODs). NDI-Plus searches retrieve COD
codes as well as date of death. Death certiﬁcate
data were coded by a nosologist. Because the
NDI does not include deaths before 1979, any
worker lost to follow-up before 1979 was clas-
siﬁed “vital status unknown” and considered
alive until the date last observed (usually the
date last employed). Death was coded to the
revision of the International Classification of
Diseases, 9th Revision [ICD-9; World Health
Organization (WHO) 1979] in effect at the
time of death. This study was approved by the
NIOSH Human Subjects Review Board. As a
records study, it was exempted from informed
consent requirements.
Statistical analysis. The standardized mor-
tality ratio (SMR) is the ratio of observed to
expected deaths. Sex/race/age/calendar period
reference rate files based on mortality in the
Indiana and U.S. populations include
99 CODs, each encompassing a number of
ICD codes, and cover the period beginning in
1960. State rates control for local conditions
that may have no association with occupational
exposures. In addition to the gradient of dis-
ease with latitude seen for infectious diseases
(Guernier et al. 2004) and some cancers
(Nomura and Kolonel 1991; Schwartz 1992),
regional differences can affect other CODs
(Mansﬁeld et al. 1999; Pickle et al. 1997). We
present Indiana-based SMRs, except as noted.
Our analyses used the NIOSH PC Life
Table Analysis System (Cassinelli et al. 1997;
NIOSH 2001; Steenland et al. 1990, 1998;
Waxweiler et al. 1983). The statistical signiﬁ-
cance of the SMR was determined by a two-
tailed test based on the Poisson distribution.
The program calculated the 95% conﬁdence
interval (CI) for each SMR estimate.
Race- and sex-speciﬁc person-years at risk
(PYAR) were accumulated for each eligible
worker across 5-year age and calendar year
intervals, beginning on 1 January 1960 or the
qualiﬁed date of ﬁrst exposure, whichever was
later, and ending with the date of death, the
date last known alive, or 31 December 1998,
the study end date. Cohort members known to
be alive after 1 January 1979 and not identiﬁed
as deceased were assumed to be alive on
31 December 1998. Latency began at the date
of first exposure and ended with the date of
death, the date last known alive, or on
31 December 1998. For analyses we used the
Indiana and U.S. 99-COD rate ﬁles. Using a
multiple-COD analysis (MCOD) and U.S.
rates (Steenland et al. 1992), we investigated
possible excesses in nonmalignant chronic dis-
eases. A separate analysis was restricted to indi-
viduals who worked at least 90 days (n =
2,789) a) to facilitate comparison with analyses
of New York and Massachusetts cohorts of
capacitor manufacturing workers exposed to
PCBs (Brown 1987; Brown and Jones 1981;
Kimbrough et al. 1999, 2003) and b) because
there appear to be lifestyle and mortality dif-
ferences between short-term and long-term
workers (Kolstad and Olsen 1999).
We calculated estimated cumulative
PCB exposure for each worker, based on job
titles, job codes, and era(s) of employment.
Cumulative exposure ranged from 10 to
1,218,590 unit-days of PCB exposure
(median, 16,860 unit-days) (Nilsen et al.
2004). Cut-points at 11,000 and 90,000 unit-
days of exposure deﬁned tertiles with approxi-
mately equal numbers of deaths. Standardized
rates were calculated for each cumulative
exposure tertile using the sum of all PYAR for
each sex/race/age/calendar time stratum as the
weight for the speciﬁc stratum. Standardized
rate ratios (SRRs) were calculated for each
higher exposure tertile relative to the lowest
tertile. Based on a Taylor series approximation
of the variance, 95% CIs were calculated and a
test for a linear trend was performed based on
a weighted regression of the standardized rates
(Rothman 1989). We used multivariate
Poisson regression modeling and SAS 9 soft-
ware (SAS Institute 2004) to adjust for sex,
age, calendar year, and latency, and to calcu-
late rate ratios (RRs) for higher exposure ter-
tiles relative to the lowest tertile. We repeated
the analysis excluding 117 workers with
potential exposure to solvents (xylene, toluene,
1,1,1-trichloroethane, and trichloroethylene).
We used original department and opera-
tion codes from plant records and a map of
exposure zones developed for the original study
(Sinks et al. 1992) to re-create exposure zone
assignments. The mortality analysis was
repeated using exposure zones.
Results
Table 1 shows the cohort stratified by race,
sex, and vital status. About one-third of the
cohort (1,176 workers, 33%) worked between
1 day and 6 months, one-third (1,133 work-
ers, 32%) 6 months to 3 years, and one-third
(1,260 workers, 35%) > 3 years. Nearly all
(97%) in the highest tertile of estimated
cumulative exposure worked > 3 years, and
nearly all (93%) in the lowest exposure tertile
worked < 3 years.
About 6% of men’s work-years and 1.2%
of women’s were in the highest exposure jobs
(salvage and repair; ﬁll, solder, impregnate; leak
tester). Men had a mean cumulative exposure
of 82,503 unit-days; the mean for women was
47,824 unit-days; 23% of men’s and 16% of
women’s PYAR fell into the highest exposure
tertile. For 221 workers who provided blood
specimens in 1977 (Smith et al. 1982), esti-
mated cumulative exposure and serum PCB
level were significantly correlated (Spearman
correlation, r = 0.37, p < 0.0001); serum PCB
level and duration of exposure were not well
correlated (Spearman correlation, r = 0.10,
p = 0.15).
Observed deaths, corresponding SMRs
using Indiana rates, and the SMR CIs are pre-
sented in Table 2 for the three exposure tertiles
and overall. Mortality overall was reduced
(547 deaths; SMR, 0.81; 95% CI, 0.7–0.9). In
race- and sex-speciﬁc analyses (not shown), the
overall statistics for white males and females
were 453 deaths (SMR, 0.82; 95% CI,
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0.6–0.9), respectively. Two deaths occurred
among 19 nonwhite female employees and
eight among 11 nonwhite male employees.
No excess deaths due to malignant neo-
plasms overall were observed (171 deaths;
SMR, 0.90; 95% CI, 0.8–1.0). In the MCOD
analysis, 268 deaths had cancer as the under-
lying or contributing cause (MCOD U.S.
SMR, 1.00; 95% CI, 0.9–1.1).
Among the a priori cancers of interest,
melanoma was in statistically signiﬁcant excess
(9 deaths; SMR, 2.43; 95% CI, 1.1–4.6). In
the original analysis (Sinks et al. 1992), there
were 8 skin cancer deaths (all melanomas)
(U.S. SMR, 4.1; 95% CI, 1.8–8.0). Seven
brain cancer deaths occurred after the previous
report (present update: 12 deaths; SMR, 1.91;
95% CI, 1.0–3.3; original study: 5 deaths,
U.S. SMR, 1.8; 95% CI, 0.6–4.2). The 12
brain cancers included 8 gliomas and 4 carci-
nomas. Review of the death certiﬁcates indi-
cated that 2 of the carcinomas (both in men)
could have been metastases. In a sensitivity
analysis to determine risk omitting those 2
deaths, brain cancer SMR decreased (10
deaths; SMR, 1.59; 95% CI, 0.8–2.9).
Non-Hodgkin lymphoma mortality, not
reported separately in the original study (Sinks
et al. 1992), was increased but not statistically
significant (9 deaths; SMR, 1.23; 95% CI,
0.6–2.3). No other subcategory of hemato-
poietic cancers (Hodgkin disease, leukemia
and aleukemia, or myeloma) showed excess
deaths (results not shown). Other cancers of a
priori interest (rectal and biliary passages, liver,
and gallbladder) were not in excess.
As is typical of a working population, the
cohort overall had no statistically significant
increased SMRs for diseases other than cancer
and generally decreased SMRs for heart dis-
eases, especially ischemic heart disease
(149 deaths; SMR, 0.84; 95% CI, 0.7–1.0).
Cardiomyopathy mortality was elevated
(13 deaths; SMR, 1.67; 95% CI, 0.9–2.9),
with a signiﬁcant excess in the lowest exposure
tertile (7 deaths; SMR, 2.79; 95% CI,
1.1–5.7). There were decreased risks for
deaths from other circulatory system diseases
(27 deaths; SMR, 0.56; 95% CI, 0.4–0.8);
digestive system diseases (14 deaths; SMR,
0.51; 95% CI, 0.3–0.9), including cirrhosis of
the liver (6 deaths; SMR, 0.43; 95% CI,
0.2–0.9); and homicide (3 deaths; SMR, 0.46;
95% CI, 0.1–1.3).
In analyses restricted to 2,789 employees
who worked at least 90 days, mortality overall
was reduced (445 deaths; SMR, 0.79;
95% CI, 0.7–0.9), as was cancer overall (136
deaths; SMR, 0.85; 95% CI, 0.7–1.0). Both
melanoma (8 deaths; SMR, 2.66; 95% CI,
1.1–5.2) and brain cancer (11 deaths; SMR,
2.12; 95% CI, 1.1–3.8) were in excess, espe-
cially among women: 3 melanoma deaths
(SMR, 5.99; 95% CI, 1.2–17.5) and 3 brain
cancer deaths (SMR, 2.87; 95% CI, 0.6–8.4).
Eliminating 1 male brain cancer death that
could have been a metastasis would change the
overall SMR to 1.93 (95% CI, 0.9–3.6) and
the SMR among men to 1.69 (95% CI,
0.7–3.5). The non-Hodgkin lymphoma mor-
tality increase was not statistically signiﬁcant
(8 deaths; SMR, 1.31; 95% CI, 0.6–2.6), but
the rate was higher among women (3 deaths;
SMR, 2.42; 95% CI, 0.5–7.1). As in the
cohort overall, mortality from heart disease,
digestive system disease, and homicide was
reduced (results not shown). Cardiomyopathy
mortality remained elevated (10 deaths; SMR,
1.55; 95% CI, 0.7–2.8) and occurred exclu-
sively in men (SMR, 1.82; 95% CI, 0.9–3.3).
Table 2 provides Indiana-based SMRs for
the three exposure tertiles for all CODs. For
both overall mortality and all cancer, there was
no signiﬁcant trend with increasing estimated
cumulative exposure (Table 3). Table 3 pre-
sents SRRs and RRs (adjusted for sex, age, cal-
endar year, and latency) for melanoma and
brain cancer. Melanoma was in excess in the
lowest tertile (5 deaths; SMR, 3.72; 95% CI,
1.2–8.7), but the trend test was not signifi-
cant. Brain cancer mortality increased with
exposure (5 deaths in the highest tertile; SMR,
2.71; 95% CI, 0.9–6.3); 3 of the 5 deaths
were among women. SMRs, SRRs, and RRs
increased with increasing exposure, but only
the SRR dose–response trend was statistically
signiﬁcant (p = 0.016). In the sensitivity analy-
sis, when we excluded 2 brain cancer deaths
that could have been metastases, results by ter-
tile changed [lowest tertile: 2 deaths; SMR,
0.92 (95% CI, 0.1–3.3); SRR 1.0; middle ter-
tile: 4 deaths; SMR, 1.79 (95% CI, 0.5–4.6);
SRR 1.64 (95% CI, 0.3–9.0); highest tertile:
4 deaths; SMR, 2.17 (95% CI, 0.6–5.6); SRR
1.96 (95% CI, 0.4–11.1)]. The SRR dose–
response trend remained statistically signifi-
cant (p = 0.01).
We reran the analysis excluding those
(n = 117) with potential solvent exposure. No
melanoma or brain cancer deaths occurred
among the solvent-exposed workers. Results
for all deaths and all cancer deaths did not
change signiﬁcantly (data not shown).
We repeated the estimated cumulative
exposure analysis using the exposure zones
developed for the original study. Results (data
not shown) were similar to those using the
JEM: brain cancer was associated with higher
levels of exposure, but no dose–response rela-
tionship between estimated cumulative PCB
exposure and melanoma was found. Analysis of
the 153 deaths among the 1,139 workers who
ever worked in the highest exposure zone iden-
tiﬁed in the original study (Sinks et al. 1992)
demonstrated no increase in risk with time
worked for all deaths or cancer deaths (data not
shown). Comparing the original study expo-
sure model with the two JEMs gave Spearman
correlations of r = 0.6 (p < 0.0001) for the
inhalation JEM and r = 0.4 (p < 0.0001) for
the dermal JEM.
For cancer overall, stratifying by latency
(time from first exposure to death) did not
affect mortality [< 10 years: 11 deaths; SMR
0.80 (95% CI, 0.4–1.4); 10 to < 20 years:
37 deaths, SMR 1.03 (95% CI, 0.7–1.4);
≥ 20 years: 122 deaths, SMR 0.88 (95% CI,
0.7–1.0)]. Brain cancer mortality was elevated
in each latency period [< 10 years: 2 deaths,
SMR 2.44 (95% CI, 0.3–8.8); 10 to < 20
years: 4 deaths, SMR 2.63 (95% CI, 0.7–6.7);
Ruder et al.
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Table 1. NIOSH Indiana capacitor cohort as of 31 December 1998.
Characteristic No.,  %
Total workers 3,643
Excluded from analysisa 74
Race, sex, and vital status
No. (no. of deaths, % dead in stratumb)
White females 833 (84, 10%)
Nonwhite females 19 (2, 11%)
White males 2,706 (453, 17%)
Nonwhite males 11 (8, 73%)
Total analyzed 3,569 (547, 15%)
Age at ﬁrst employment (years)
Median 24
Mean ± SD 27 ± 8.2
Duration of employment (years)
Median 1.3
Mean ± SD 3.9 ± 5.3
Estimated cumulative exposure (unit-days)c 22% worked 43% worked 35% worked
< 90 days 90 days to < 3 years ≥ 3 years
Lowest tertile (0 to < 11,000)  753, 97% 634, 42% 105, 8%
Middle tertile 21, 3% 867, 57% 371, 30%
Highest tertile (≥ 90,000) 0 22, 1% 775, 62%
PYAR 108,930
aForty-one workers were missing employment dates, 1 stopped working before PCBs were used, 1 worked < 1 day, 26 were
missing date of birth, and 5 were lost to follow-up before 1960. bSubjects coded as “alive” include 104 persons with vital
status unknown (considered alive until the date lost to follow-up). cEstimated cumulative exposure could not be calculated
for 21 workers with periods of unknown exposure level.≥ 20 years: 6 deaths, SMR 1.53 (95% CI,
0.6–3.3)]. Melanoma mortality was elevated
among workers with shorter but not longer
latency [< 10 years: 2 deaths, SMR 4.71 (95%
CI, 0.6–17.0); 10 to < 20 years: 5 deaths, SMR
5.03 (95% CI, 1.6–11.7); ≥ 20 years: 2 deaths,
SMR 0.88 (95% CI, 0.1–3.2)].
Discussion
Studies of mortality in cohorts occupationally
exposed to PCBs present inconsistent find-
ings. Nine cohorts of electrical capacitor and
transformer manufacturers have been studied
in, to date, 17 reports in the literature or in
unpublished documents [see Supplemental
Material (http://ehp.niehs.nih.gov/docs/2005/
8253/supplement.pdf)]. In some cases SMRs
were elevated for one sex but not the other.
Excess deaths from particular cancers or other
diseases have been reported, but there has
been little consistency from cohort to cohort,
or even within cohorts across studies.
Brown (1987) found excess liver cancer
among the high-exposed group (1,607
workers) within a Massachusetts capacitor
manufacturing cohort (4 deaths; SMR, 3.3;
95% CI, 0.9–9.3), with all four deaths
occurring in women (SMR, 4.4; 95% CI,
1.2–12.3). Taylor et al. (1988) expanded the
New York cohort to all those working 90 days
or more (6,292 workers) and found a slight
excess of digestive system cancer (44 deaths;
SMR, 1.3; 95% CI, 1.0–1.8), whereas
Kimbrough et al. (1999, 2003), studying a
reexpanded New York cohort (n = 7,075)
reported no cancer SMR excesses.
Three studies of the same Italian factory
(Bertazzi et al. 1982, 1987; Tironi et al.
1996) reported elevated SMRs for lymphatic
and hematopoietic cancers, and digestive sys-
tem cancers in men. Swedish male capacitor
manufacturing workers (Gustavsson et al.
1986; Gustavsson and Hogstedt 1997) had
no increased mortality risk, whereas Canadian
transformer manufacturing workers had
excess pancreatic cancer, especially in the
transformer assembly department (4 deaths;
SMR, 9.8; 95% CI, 2.6–25) (Yassi et al.
1994). Transformer manufacturing workers
in Massachusetts exposed to PCBs had an
odds ratio of 3.3 (95% CI 1.1–9.3) for lym-
phoma, compared with co-workers not PCB-
exposed (Greenland et al. 1994). In an Illinois
capacitor manufacturing facility, Mallin et al.
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Table 2. Mortality in the NIOSH Indiana capacitor cohort for selected causes, by exposure tertile and overall, based on Indiana state rates for 1960–1998.
Lowest tertilea Middle tertile Highest tertile Overallb
Underlying CODc (ICD-9 codes) nd SMR 95% CI n SMR 95% CI n SMR 95% CI n SMR 95% CI
All cancers (140–208) 56 0.94 (0.7–1.2) 62 0.93 (0.7–1.2) 52 0.83 (0.6–1.1) 171 0.90 (0.8–1.0)
Buccal and pharyngeal (140–149) 2 1.97 (0.2–7.1) 0 1 0.88 (0.0–4.9) 3 0.90 (0.2–2.6)
Digestive system (150–159) 14 1.13 (0.6–1.9) 14 0.99 (0.5–1.7) 11 0.80 (0.4–1.4) 39 0.96 (0.7–1.3)
Esophagus (150) 2 1.47 (0.2–5.3) 2 1.27 (0.2–4.6) 3 1.95 (0.4–5.7) 7 1.55 (0.6–3.2)
Stomach (151) 3 2.40 (0.5–7.0) 0 2 1.47 (0.2–5.3) 5 1.23 (0.4–2.9)
Intestine (except rectum) (152–153) 7 1.43 (0.6–3.0) 4 0.72 (0.2–1.8) 4 0.74 (0.2–1.9) 15 0.94 (0.5–1.5)
Rectum (154) 0 1 0.97 (0.0–5.4) 0 1 0.34 (0.0–1.9)
Biliary passages, liver, and gallbladder (155, 156) 0 2 1.46 (0.2–5.3) 0 2 0.51 (0.1–1.8)
Pancreas (157) 2 0.77 (0.1–2.8) 5 1.69 (0.5–3.9) 2 0.70 (0.1–2.5) 9 1.06 (0.5–2.0)
Respiratory system (160–165) 16 0.77 (0.4–1.3) 24 0.98 (0.6–1.5) 19 0.79 (0.5–1.2) 59 0.85 (0.6–1.1)
Trachea, bronchus, and lung (162) 16 0.80 (0.5–1.3) 24 1.02 (0.7–1.5) 19 0.82 (0.5–1.3) 59 0.88 (0.7–1.1)
Breast (174–175) 4 1.04 (0.3–2.7) 3 0.92 (0.2–2.7) 0 8 0.83 (0.4–1.6)
Male genital organs (185–186) 1 0.43 (0.0–2.4) 2 0.69 (0.1–2.5) 1 0.32 (0.0–1.8) 4 0.47 (0.1–1.2)
Prostate (185) 1 0.48 (0.0–2.7) 2 0.76 (0.1–2.7) 1 0.33 (0.0–1.8) 4 0.51 (0.1–1.3)
Urinary organs (188–189) 1 0.39 (0.0–2.2) 1 0.34 (0.0–1.9) 2 0.71 (0.1–2.6) 4 0.48 (0.1–1.2)
Kidney (189.0–189.2) 0 1 0.55 (0.0–3.0) 1 0.59 (0.0–3.3) 2 0.38 (0.0–1.4)
Bladder and other urinary organs (188, 189.3–189.9) 1 1.11 (0.0–6.2) 0 1 0.87 (0.0–4.9) 2 0.63 (0.1–2.3)
Other and unspeciﬁed sites (170–173, 187, 190–199) 13 1.54 (0.8–2.6) 8 0.88 (0.4–1.7) 13 1.63 (0.9–2.8) 34 1.32 (0.9–1.9)
Melanoma (172) 5 3.72* (1.2–8.7) 2 1.51 (0.2–5.4) 2 1.97 (0.2–7.1) 9 2.43* (1.1–4.6)
Brain and nervous system (191–192) 3 1.38 (0.3–4.0) 4 1.79 (0.5–4.6) 5 2.71 (0.9–6.3) 12 1.91 (1.0–3.3)
Other and unspeciﬁed sites (187, 194–199) 5 1.25 (0.4–2.9) 1 0.22 (0.0–1.2) 5 1.17 (0.4–2.7) 11 0.86 (0.4–1.5)
Lymphatic and hematopoietic (200–208) 5 0.82 (0.3–1.9) 10 1.53 (0.7–2.8) 5 0.87 (0.3–2.0) 20 1.08 (0.7–1.7)
Non-Hodgkin lymphoma (200, 202) 1 0.42 (0.0–2.3) 5 1.93 (0.6–4.5) 3 1.30 (0.3–3.8) 9 1.23 (0.6–2.3)
Diabetes mellitus (250) 2 0.42 (0.1–1.5) 3 0.58 (0.1–1.7) 5 1.03 (0.3–2.4) 10 0.67 (0.3–1.2)
Blood and blood-forming diseases (281–289) 0 1 1.40 (0.0–7.8) 0 1 0.49 (0.0–2.7)
Alcoholism and mental disorders (290–319) 1 0.54 (0.0–3.0) 2 1.03 (0.1–3.7) 0 3 0.54 (0.1–1.6)
Nervous system diseases (320–337, 340–389) 0 3 0.82 (0.2–2.4) 2 0.60 (0.1–2.2) 5 0.47 (0.2–1.1)
Diseases of the heart (390–398, 402, 404, 410–414, 420–429) 48 0.76 (0.6–1.0) 64 0.85 (0.7–1.1) 67 0.90 (0.7–1.1) 179 0.83* (0.7–1.0)
Ischemic heart disease (410–414, 429.2) 37 0.72* (0.5–1.0) 58 0.94 (0.7–1.2) 54 0.88 (0.7–1.1) 149 0.84* (0.7–1.0)
Cardiomyopathy (425) 7 2.79* (1.1–5.7) 3 1.10 (0.2–3.2) 3 1.20 (0.2–3.5) 13 1.67 (0.9–2.9)
Other circulatory system (401, 403, 405, 415–417, 430–438, 440–459) 10 0.70 (0.3–1.3) 8 0.48* (0.2–0.9) 8 0.48* (0.2–1.0) 27 0.56** (0.4–0.8)
Respiratory system (460–466, 470–478, 480–487, 490–519) 10 0.78  (0.4–1.4) 14 0.93  (0.5–1.6)  12  0.77 (0.4–1.3)  37  0.85 (0.6–1.2)
Digestive system (520–537, 540–543, 550–553, 555–558, 560, 562–579) 8 0.90  (0.4–1.8) 3 0.31* (0.1–0.9)  3  0.35 (0.1–1.0)  14  0.51**  (0.3–0.9)
Cirrhosis of liver (571) 5 1.10 (0.4–2.6) 0 1 0.23 (0.0–1.3) 6 0.43* (0.2–0.9)
Genitourinary system (580–608, 610, 611, 614–629) 2 0.80 (0.1–2.9) 0 1 0.37 (0.0–2.1) 3 0.37 (0.1–1.1)
Skin and subcutaneous tissue (680–686, 690–709) 0 1 5.94 (0.2–33.1) 0 1 2.09 (0.1–11.6)
Symptoms and ill-deﬁned conditions (780–796, 798, 799) 2 1.24 (0.2–4.5) 1 0.64 (0.0–3.6) 0 3 0.69 (0.1–2.0)
Accidents (E800–E848, E850–E888, E890–E949) 19 0.85 (0.5–1.3) 12 0.59 (0.3–1.0) 14 1.18 (0.6–2.0) 45 0.82 (0.6–1.1)
Suicide (E950–E959) 6 0.72 (0.3–1.6) 6 0.77 (0.3–1.7) 7 1.41 (0.6–2.9) 19 0.90 (0.5–1.4)
Homicide (E960–E978) 2 0.71 (0.1–2.6) 1 0.42 (0.0–2.3) 0 3 0.46 (0.1–1.3)
HIV related (042–044) 3 3.16 (0.7–9.2) 0 0 3 1.42 (0.3–4.1)
Other causes (residual codes) 4 0.77 (0.2–2.0) 3 0.59 (0.1–1.7) 6 1.47 (0.5–3.2) 13 0.90 (0.5–1.5)
CODs not obtained 7 1 2 10
All causes 180 0.84* (0.7–1.0) 185 0.78** (0.7–0.9) 179 0.83* (0.7–1.0) 547c 0.81** (0.7–0.9)
aLowest tertile deﬁned by cumulative exposure < 11,000 unit-days and highest tertile by cumulative exposure ≥ 90,000 unit-days. bTotal is greater than sum of tertiles because cumulative
exposure could not be estimated for 21 workers, including 3 deceased workers with periods of employment lacking exposure data. cCategories omitted because no deaths occurred
include female genital organ cancers (ICD-9 codes 179–184), benign neoplasms (210–239), tuberculosis (010–018), and musculoskeletal diseases (710–721, 730). dObserved number of
deaths. *p < 0.05. **p < 0.01.(2004) found excess gastrointestinal cancer,
especially among those working 5 or more years
between 1952 and 1977 [men, 3 stomach can-
cer deaths (SMR, 3.09; 95% CI, 0.6–9.0);
women, 9 intestinal cancer deaths (SMR, 2.25;
95% CI, 1.0–4.3) and 4 liver cancer deaths
(SMR, 5.57; 95% CI, 1.5–14.3)]. The original
report on our cohort found three skin cancer
(all melanoma) deaths (SMR, 7.0; 95% CI,
1.4–23) and three brain cancer deaths (SMR,
4.8; 95% CI, 1.0–16) among those employed
at least 10 years (Sinks et al. 1992).
Some of these cohort studies are unin-
formative due to small sample size, insuffi-
cient latency, or problems in study design.
Differences in ﬁndings between cohorts could
be due to differences in materials or work prac-
tices; each plant potentially had a unique pat-
tern of exposures. Although air concentrations
are expressed in standard units that permit
comparisons across plants, dermal exposure
measurements are not, and dermal exposure is
a signiﬁcant route for PCBs (Lees et al. 1987;
Safe 1984; Smith et al. 1982; Wolff et al.
1982). Different results in studies of the same
cohort could be due to variations in study eligi-
bility criteria, in choice of comparison groups,
or in how results were presented.
Several studies have reported signiﬁcantly
higher serum or adipose tissue levels of PCBs
in cancer cases than in controls (Aronson et al.
2000; Charlier et al. 2004; Howsam et al.
2004; Rothman et al. 1997). Others have seen
no association of serum PCB and cancer risk
(Dorgan et al. 1999; Gammon et al. 2002;
Rusiecki et al. 2004; Ward et al. 2000). It
should be noted that in all these studies,
whether blood was collected prospectively in
the 1970s when PCB use was widespread or
retrospectively 20–30 years later when mean
serum levels had decreased by 80–90%
(Schecter et al. 2005), serum levels among the
environmentally exposed would be much
lower than among the occupationally exposed.
For example, archived 1974 serum samples of
Maryland residents had mean levels of 7.56
and 6.55 ng PCBs/mL for non-Hodgkin lym-
phoma cases and controls, respectively
(Rothman et al. 1997), whereas workers from
the Indiana plant had mean 1977 levels of
546 and 111 ng PCBs/mL serum for the most
and least exposed workers, respectively (Smith
et al. 1982).
As in many cohort mortality studies, lim-
ited data were available to construct the JEM:
individual work histories, detailed job descrip-
tions for hourly jobs, and 56 measurements
collected at the plant in 1977. The JEM used
proximity to the ovens, as did the zone classiﬁ-
cation used in the original study (Sinks et al.
1992), but also incorporated job descriptions,
plant layouts, workers’ mobility, exposure
intensity and frequency, inhalation and dermal
exposure to PCBs, and exposure to other
chemicals. Analyses replicating the exposure
zones from the original study yielded results
similar to those using the JEM (brain cancer
was associated with higher levels of exposure;
there was no dose–response relationship
between estimated cumulative PCB exposure
and melanoma). Mortality did not increase
with time worked in the highest exposure zone.
The zone exposure model and inhalation and
dermal JEMs were signiﬁcantly correlated. An
independent measure of cumulative exposure
is body burden. Serum collected from 221
Indiana workers in 1977 was analyzed for
PCBs (Smith et al. 1982). Cumulative expo-
sure estimated with the JEM and serum PCB
levels were signiﬁcantly correlated.
Our ﬁndings conﬁrm those of the original
study (Sinks et al. 1992) of excess melanoma
and brain cancer mortality. Although no other
study of capacitor manufacturing workers
found elevated SMRs for these sites, a study of
transformer manufacturing observed an ele-
vated standardized incidence ratio (SIR) for
brain cancer among males ever in PCB-
exposed jobs (4 diagnoses; SIR, 4.4; 95% CI,
1.2–12) (Liss 1989). Excess melanoma was
reported (Bahn et al. 1976) for PCB-exposed
employees of a New Jersey petrochemical plant
(2 cases; SIR, 50; 95% CI 5.6–217). Nine
employees of Norwegian hydroelectric power
plants ever exposed to PCBs had melanoma
(SIR, 1.8; 95% CI, 0.8–3.6), with risk concen-
trated among those who also had > 15 µT
years of magnetic ﬁeld exposure versus fewer
years (9 cases; SIR, 2.7; 95% CI, 1.2–5.2) or
> 30 exposure-years to electrical discharges
versus fewer years (7 cases; SIR, 2.8; 95% CI,
1.1–6.0) (Tynes et al. 1994). Loomis et al.
(1997) found excess melanoma mortality in a
large cohort of electric utility workers, with
increasing risk for increasing cumulative expo-
sure, as well as increased brain cancer risk
among workers in the two intermediate (but
not the highest) quartiles of exposure. 
We found higher SMRs among women for
both melanoma and brain cancer. Men, how-
ever, generally had jobs with higher exposure as
well as higher cumulative PCB exposure. Some
interaction between estrogenic PCBs and hor-
mones may contribute to the higher risk for
women (Gore et al. 2002; Soontornchat et al.
1994). Because women have a higher percent-
age of adipose tissue, PCBs may be stored in
their bodies longer (Brown 1994).
Our sensitivity analysis of the brain cancer
deaths (8 gliomas and 4 carcinomas), excluding
2 carcinomas that could have been metastasis,
still found the highest SMRs and SRRs among
workers in the highest tertile of estimated
cumulative exposure. An analysis excluding
117 workers with potential solvent exposure at
the plant did not affect melanoma or brain
cancer mortality. Stratifying by latency (time
from first exposure to death) did not affect
mortality for cancer overall and for brain can-
cer. Melanoma mortality was elevated among
workers with shorter but not longer latency.
As in most cohort studies, we had no infor-
mation on risk factors such as family history or
genetic susceptibility; lifestyle choices, such as
sun exposure, that could affect mortality; or on
previous or subsequent employment. This last
limitation is significant for the two-thirds of
the cohort who worked < 3 years in the plant.
(It should be noted that 97% of workers in the
highest tertile, with the highest brain cancer
risk, worked ≥ 3 years.)
Increased mortality among short-term
workers has been reported, particularly for
CODs associated with disorders that might
affect employment or with an unhealthy
lifestyle. Kolstad and Olsen (1999) found that
shorter durations of employment were associ-
ated with more preemployment hospitaliza-
tions for alcohol use, accidents, and the effects
of violence. We have no lifestyle or hospitaliza-
tion information for our cohort. However,
when short-term workers were excluded from
the analysis, the already low SMRs for cirrhosis
of the liver and homicide (Table 2) dropped
even farther, whereas the SMRs for melanoma
and brain cancer increased.
In conclusion, we found evidence of an
association between employment at this plant
and melanoma and brain cancer mortality. We
used a JEM that incorporated both inhalation
and dermal exposure potentials to estimate
cumulative exposure. However, melanoma
Ruder et al.
22 VOLUME 114 | NUMBER 1 | January 2006 • Environmental Health Perspectives
Table 3. NIOSH Indiana capacitor cohort: mortality from selected CODs according to estimated cumulative
exposure to PCBs.
Cumulative exposure (unit-days)
< 11,000 11,000–89,999 ≥ 90,000 Trend
Underlying COD n Ratio (95% CI) n Ratio (95% CI) n Ratio (95% CI) p-value
All causes SMRa 180 0.84 (0.7–1.0)* 185 0.78 (0.7–0.9)** 179 0.83 (0.7–1.0)* 0.84
All cancers SMR 56 0.94 (0.7–1.2) 62 0.93 (0.7–1.2) 52 0.83 (0.6–1.1) 0.48
Melanoma SMR 5 3.72 (1.2–8.7)* 2 1.51 (0.2–5.4) 2 1.97 (0.2–7.1) 0.62
SRR 1 0.38 (0.1–2.0) 0.58 (0.1–3.5) 0.72
RRb 1 0.43 (0.1–2.3) 0.59 (0.1–3.2) 0.71
Brain cancer SMR 3 1.38 (0.3–4.1) 4 1.79 (0.5–4.6) 5 2.71 (0.9–6.3) 0.34
SRR 1 1.01 (0.2–4.6) 1.48 (0.3–6.4) 0.016
RR 1 1.29 (0.3–5.8) 1.95 (0.4–8.5) 0.37
aSMR using Indiana rates. bObtained via Poisson regression, adjusted for sex, age (< 50, ≥ 50 years), calendar year (before
1980, after 1980), and latency (< 10, 10–19, ≥ 20 years). *p < 0.05. **p < 0.01.Mortality in PCB-capacitor manufacturing
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mortality was not associated with estimated
cumulative PCB exposure, and for brain can-
cer, the association between mortality and esti-
mated PCB cumulative exposure did not
demonstrate a clear dose–response relationship.
The cancer incidence study we are con-
ducting on this cohort (and the New York and
Massachusetts NIOSH cohorts) may provide
some additional insight.
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